A study focusing on the contribution of genetics, specifically germline BRCA1, BRCA2, TP53, and PALB2 mutations in breast cancer patients in Brunei Darussalam, showed that 4.2% of the patients were attributed to germline BRCA2 mutations (Matusin, 2020). The gene discussed is BRCA1; the disease is breast carcinoma.